Brentuximab vedotin (BV) versus physician’s choice (PC) of methotrexate or bexarotene in adult patients with previously treated CD30-positive cutaneous T-cell lymphoma (CTCL; mycosis fungoides [MF] or primary cutaneous anaplastic large cell lymphoma [pcALCL]): final time to next therapy (TTNT) results from the phase 3 ALCANZA study
Titel:
Brentuximab vedotin (BV) versus physician’s choice (PC) of methotrexate or bexarotene in adult patients with previously treated CD30-positive cutaneous T-cell lymphoma (CTCL; mycosis fungoides [MF] or primary cutaneous anaplastic large cell lymphoma [pcALCL]): final time to next therapy (TTNT) results from the phase 3 ALCANZA study
Auteur:
Scarisbrick, Julia Horwitz, Steven M. Prince, H. Miles Whittaker, Sean Duvic, Madeleine Kim, Youn H. Quaglino, Pietro Zinzani, Pier Luigi Bechter, Oliver Eradat, Herbert Pinter-Brown, Lauren Akilov, Oleg Geskin, Larisa Sanches, Jose Ortiz-Romero, Pablo Lisano, Julie Brown, Lisa Bunn, Veronica Little, Meredith Dummer, Reinhard